ABSTRACT
Introduction The target glycosylated haemoglobin (HbA1c) at which macrovascular benefits may be derived in type 2 diabetes (T2D) has never been clearly outlined. This meta-analysis was conducted on fifteen randomized controlled trials to highlight the association of HbA1c range with macrovascular events.
Methods The association of different HbA1c clusters (intention to treat (ITT) and end-of-study [EOS]) range (less or equal than 6.5%, 6.6%–7.0%, 7.1%–7.7%) with macrovascular complications and also the combined effect of duration of T2D (< 10 years or ≥ 10 years) and HbA1c levels was assessed.
Results Intensive glucose-lowering strategy resulted in a significant 13% reduction in non-fatal myocardial infarction (NFMI) (P=0.006). Based on HbA1c achieved, a significant 36% reduction in non-fatal stroke (P=0.008) and a 22% reduction in all-cause mortality (P=0.02) were observed in the group with HbA1c between 7.1% – 7.7% irrespective of diabetes duration. In the cohort, with diabetes duration <10 years, reduction of HbA1c in the range7.1% - 7.7% resulted in a significant 36% reduction in non-fatal stroke (NFS) (P<0.001).
Conclusion This is probably the first meta-analysis highlighting the importance of treating patients with T2D to a target HbA1C of 7 – 7.7%, as this target is associated with reduction in macrovascular events.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CRD42019122403
Funding Statement
No external funding was received for this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nightingale Hospital ethical committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was available online.
Abbreviations
- ADA
- American Diabetes Association
- ACP
- American College of Physicians
- AACE
- American Association of Clinical Endocrinologists
- CDA
- Canadian Diabetes Association
- NICE
- National Institute for Clinical Excellence
- IDF
- International Diabetes Federation
- T2DM
- Type 2 DM
- DM
- Diabetes Mellitus
- CDC
- The Centers for Disease Control and Prevention
- HbA1c
- Glycated haemoglobin C
- CKD
- Chronic Kidney Disease
- GBD
- Global Burden of Disease
- CV deaths
- Cardiovascular deaths
- EOS
- End-of-Study
- ESRD
- end-stage renal disease
- HR
- Hazard Ratio
- CI
- Confidence Interval
- DPN
- Diabetic Peripheral Neuropathy
- IC
- Intensive Control
- CC
- Conventional Control
- hHF
- Hospitalisation for Heart Failure
- NFMI
- Non-Fatal Myocardial Infarction
- NFS
- Non-Fatal Stroke
- ACM
- All-Cause Mortality